Linda Osborne, DO
Urology · Gahanna, OHNPI 1861463721
Payments from drug & device makers
Across 179 payments — averaging $41.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- AbbVie$508
- Astellas Pharma US Inc$411
- Immunitybio, Inc.$263
- Progenics Pharmaceuticals, Inc.$213
- Boston Scientific$207
- plus $2K from 31 others
What the payments were for
- Travel & lodging$2,43533%
- Food & beverage$4,85666%
- Education$521%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 35 | $3,472 |
| AbbVie(2 entities) | 22 | $508 |
| Astellas Pharma US Inc | 14 | $411 |
| Immunitybio, Inc. | 5 | $263 |
| Progenics Pharmaceuticals, Inc. | 2 | $213 |
| Boston Scientific | 4 | $207 |
| Sumitomo Pharma America, Inc. | 9 | $203 |
| Axonics, Inc. | 7 | $179 |
| Endo USA, Inc. | 7 | $159 |
| Merck | 3 | $156 |
| Olympus America Inc. | 1 | $150 |
| Urovant Sciences Inc | 6 | $134 |
| Pfizer | 6 | $119 |
| Endo Pharmaceuticals Inc. | 7 | $117 |
| Johnson & Johnson | 5 | $106 |
| Urogen Pharma, Inc. | 6 | $103 |
| Bluewind Medical | 2 | $89 |
| Rochester Medical Corporation | 2 | $89 |
| Histosonics, Inc. | 1 | $74 |
| Kowa Pharmaceuticals America, Inc. | 4 | $73 |
| Antares Pharma, Inc. | 4 | $68 |
| Laborie Medical Technologies Corp. | 4 | $65 |
| Myovant Sciences Inc. | 3 | $61 |
| Neotract Inc. | 2 | $46 |
| Bayer | 2 | $39 |
| Tolmar, Inc. | 2 | $38 |
| Tolmar Pharmaceuticals, Inc. | 2 | $31 |
| Teleflex LLC | 2 | $29 |
| Sun Pharmaceutical Industries Inc. | 1 | $26 |
| Blue Earth Diagnostics | 1 | $21 |
| 180 Medical, Inc. | 1 | $18 |
| AstraZeneca | 1 | $18 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $18 |
| Procept Biorobotics Corporation | 1 | $15 |
| Calyxo, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Innovative Medical Technologies, LLC | 2 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,343 in reported general payments places this provider in the 70th percentile of 485 urology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 180 | $133,528 |
| MyrbetriqMirabegron | 70 | $56,045 |
| Methenamine Hippurate | 259 | $15,764 |
| Estradiol | 86 | $8,529 |
| Trospium Chloride ErTrospium Chloride | 28 | $7,048 |
| Trimethoprim | 65 | $5,378 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 13 | $4,181 |
| Oxybutynin Chloride ErOxybutynin Chloride | 157 | $4,093 |
| Desmopressin Acetate | 83 | $3,892 |
| Solifenacin Succinate | 69 | $3,692 |
| Potassium Citrate ErPotassium Citrate | 41 | $3,423 |
| Trospium Chloride | 48 | $2,940 |
| Tamsulosin Hcl | 197 | $2,583 |
| Dutasteride | 70 | $2,111 |
| YuvafemEstradiol | 11 | $1,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $203 | $133,528180 claims |
| Astellas Pharma US IncMyrbetriq | $411 | $56,04570 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 485 urology providers in Ohio.
Other urology in Gahanna
- Benjamin MartinGahanna$1.1M
- Jeffrey CareyGahanna$206K
- Rashmi PatelGahanna$111K
- Edward Bradley PewittGahanna$107K
- Marc PliskinCincinnati$20.8M
- Lawrence GervasiMiddleburg Heights$4.7M
- Martin FritzhandCincinnati$4.6M
- Kamal PoharCincinnati$3.4M
- Eric SingerColumbus$2.1M
- Howard GoldmanCleveland$747K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.